Physician profile
Sunitha Gubbala
NPI 1992761118
$677.58
in general payments reported to CMS, 2019-2025
15 companies · $23.79 in 2025
The $23.79 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $384 · 2020: $47.90 · 2021: $51.36 · 2022: $101 · 2023: $41.40 · 2024: $28.49 · 2025: $23.79.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $93.68.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $93.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $155.28 | 2019-2024 | Shingrix, Arexvy, Bexsero |
| Pfizer INC. | $117.72 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $69.83 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $67.68 | 2019 | |
| Novo Nordisk INC | $45.69 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $43.87 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.99 | 2019 | |
| Exact Sciences Corporation | $23.79 | 2025 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $19.62 | 2019 | |
| Sanofi Pasteur INC. | $18.48 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.22 | 2019 | |
| Abbvie INC. | $17.19 | 2019 | |
| Lilly USA, LLC | $17.01 | 2019 | |
| Bausch Health US, LLC | $15.27 | 2019 | |
| Merck Sharp & Dohme LLC | $14.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sunitha Gubbala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.